 
| Course: |
Novel Agents in the Treatment of Lung Cancer: New Approaches to First-Line Therapy |
| Target Audience: |
This educational activity is intended for oncologists and other medical professionals who assess, treat, and counsel patients with lung cancer.
Program Overview:
Results of important recent clinical studies of first-line EGFR TKI therapies, antibodies combined with chemotherapy, consolidation and up-front supportive care are creating the potential to change the paradigm for what constitutes appropriate first-line care for non–small cell lung cancer (NSCLC) patients. Medical professionals who work with lung cancer patients need to understand the results of these new studies, assess their implications for the management of NSCLC, and integrate this information into their practice of assessing, counseling and treating individual patients.
Companion CME Activity:
A companion CME activity, Lung Cancer: Case Studies Assessing Novel Agents in First-Line Therapy, based on videotaped discussion of cases is available on freeCME.com. The activity provides more in-depth information on this topic, featuring an overview by Thomas J. Lynch, Jr, MD, and discussion of 4 cases by the same program faculty that developed this activity. The activity offers up to 2 additional AMA PRA Category 1 Credits™. |
| Sponsor: |
This activity is sponsored by InforMEDical Communications, Inc, an independent medical education company.
Grantor:
This educational activity is supported by educational grants provided by Bristol-Myers Squibb and ImClone Systems Inc., Boehringer Ingelheim Pharmaceuticals, Inc., and Genentech.
Activity content is based on presentations and discussion from the 7th Cambridge Conference on Novel Agents in the Treatment of Lung Cancer: New Approaches to First-line Therapy, held in Cambridge Massachusetts on October 2, 2009. |
| Accreditation: |
| This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) by InforMEDical Communications, Inc. InforMEDical is accredited by the ACCME to provide continuing medical education for physicians and takes responsibility for the content, quality and scientific integrity of this CME activity. |
| Credit Designation: |
| InforMEDical designates this continuing medical education activity for up to 3.0 AMA PRA Category 1 Credits™. Participants should only claim credit commensurate with the extent of their participation in the activity. |
| Faculty Listing: |
Thomas J. Lynch, Jr., MD
Director, Yale Cancer Center
Physician-in-Chief Smilow Cancer
Center at Yale – New Haven
New Haven, Connecticut
Tracy T. Batchelor, MD
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Tracey Evans, MD
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania
Panos Fidias, MD
Massachusetts General Hospital
Center for Thoracic Cancers
Boston, Massachusetts
Glenwood D. Goss, MD, FCPSA, FRCPC
Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
Nasser H. Hanna, MD
Indiana University School of Medicine
Indianapolis, Indiana
Daniel D. Karp, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Natasha Leighl, MD, MMSc, FRCPC
Princess Margaret Hospital
Toronto, Ontario, Canada
Lecia V. Sequist, MD, MPH
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Jennifer Temel, MD
Massachusetts General Hospital Cancer Center
Boston, Massachusetts |
| Subjects: |
- lung cancer
- maintenance therapy
- palliative care
- treating brain metastasis
|
| Objectives: |
- After completing this activity, participants should be able to:
- Assess the rationale and limitations for targeted antibody therapy with chemotherapy in first-line treatment of NSCLC
- Assess the role of maintenance therapy in treating advanced NSCLC
- Assess how up-front supportive care and brain metastasis management can be integrated in treatment strategies for patients with advanced NSCLC
|
| Financial Disclosure: |
Tracy T. Batchelor: Consultant: Acceleron, ImClone, EMD-Serono, Exelixis; Research Funding: AstraZeneca, Millennium, Schering-Plough.
Tracey L. Evans: Consultant: Bristol-Myers Squibb; Speakers’ Bureau: Eli Lilly, Genentech.
Glenwood D Goss: Honoraria: AstraZeneca, Hoffman-La Roche; Research Funding: AstraZeneca, Hoffman-La Roche.
Nasser H. Hanna: Honoraria: Celgene, Merck.
Daniel D. Karp: Research Funding: Pfizer.
Natasha B. Leighl: Honoraria: Bristol-Myers Squibb.
Thomas J. Lynch, Jr: Consultant: AstraZeneca, Boehringer Ingelheim, Hoffman-La Roche, Merck; Patents: Genzyme for EGFR testing; Stock: Biogen. Board of Directors/Stock: Infinity Pharmaceuticals
Lecia V Sequist: Nothing to disclose.
Jennifer Temel: Nothing to disclose.
CME Reviewers: Nothing to disclose.
InforMEDical: Melinda Lindquist: Nothing to disclose. Larry Rosenberg: Spouse employed by Bristol-Myers Squibb.
This educational activity may contain discussion of published and/or investigational uses of agents, devices or diagnostics tools that have not been approved for use by the US FDA. The opinions expressed in the activity are those of the authors, and do not reflect those of the industry supporters or CME sponsor. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Participants/readers should appraise the information presented critically and are encouraged to consult appropriate resources for any product, device or diagnostic tool mentioned in this activity.
|
- You are not currently logged in.
- To view content articles and complete the post-test for this course, please login or register now
|
|
